Description
Managing toxic glucose and fat concentrations in the vasculature remain significant challenges for diabetics. As the numbers of patients affected by the disease climbs, so secondary vascular and ophthalmic complications affecting patients continue to grow. With up to 50 million people currently affected by diabetic eye diseases and 100 million forecast by 20251, more effective therapeutics are desperately needed.
Set to double from $32bn to $64bn over the next 15 years2, the global diabetes market is set for stellar growth as changing demographics and new therapies begin entering the clinic.
Focussing on efforts to reduce hyperglycaemia, dyslipidaemia and angiopathy, Visiongain s Diabetes and Diabetic Retinopathy conference concentrates on the latest developments in this area. We bring you distilled insights from outstanding speakers in key areas including:
Full market analysis, including medical needs and commercial opportunities
Novel GLP1 receptor agonists, and SLGT2 and DPP-4 inhibitors
The use of biomarkers and imaging for the development of novel therapies for diabetes
New therapeutic targets to reduce inflammation and cardiovascular disease in diabetes
Overcoming microangiopathy and capillary occlusion
Epidemiology and pharmacotherapies for diabetic eye diseases
The effects of ACE, RAS and PKC inhibitors on the progression of diabetic retinopathies
Clinical results from the EUCLID, DIRECT and RASS and FIELD studies
New data on intravitreal VEGF and PLGF signalling inhibitors
Corticosteroid implants to reduce intra-ocular vascular permeability and oedema
Blockade of the kallikrein-kinin system to treat diabetic retinopathy
